solo per uso di ricerca
N. Cat.: S3728
Struttura chimica
| Target correlati | HDAC Caspase Proteasome Secretase MMP Cysteine Protease Tyrosinase HIV Protease DPP Serine Protease |
|---|---|
| Altro HCV Protease Inibitori | Danoprevir Lomibuvir (VX-222) Asunaprevir Tizoxanide PSI-6206 (GS-331007) Mecarbinate Tegobuvir Herba taxilli Extract 2'-C-Methylcytidine Voxilaprevir |
| Linee cellulari | Tipo di saggio | Concentrazione | Tempo di incubazione | Formulazione | Descrizione dell'attività | PMID |
|---|---|---|---|---|---|---|
| HuH7 | Antiviral assay | 72 hrs | Antiviral activity against HCV genotype 1a infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by RT-PCR method, EC50=0.0003μM. | 26819676 | ||
| HuH7 | Antiviral assay | 72 hrs | Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by RT-PCR method, EC50=0.0003μM. | 26819676 | ||
| HuH7 | Antiviral assay | 72 hrs | Antiviral activity against HCV genotype 1a infected in human HuH7 cells assessed as reduction viral RNA level after 72 hrs by RT-PCR method, EC50=0.0006μM. | 27994759 | ||
| HuH7 | Antiviral assay | 72 hrs | Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as reduction viral RNA level after 72 hrs by RT-PCR method, EC50=0.0006μM. | 27994759 | ||
| HuH7 | Antiviral assay | 72 hrs | Antiviral activity against HCV genotype 2a infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by RT-PCR method, EC50=0.0012μM. | 26819676 | ||
| HuH7 | Antiviral assay | 72 hrs | Antiviral activity against Hepatitis C virus genotype 1b infected in HuH7 cells assessed as reduction in replicon RNA level after 72 hrs by TaqMan-based RT-PCR analysis in presence of 10% FBS, EC50=0.0015μM. | 24900818 | ||
| HuH7 | Antiviral assay | 72 hrs | Antiviral activity against HCV genotype 2b infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by RT-PCR method, EC50=0.005μM. | 26819676 | ||
| HuH7 | Antiviral assay | 72 hrs | Antiviral activity against HCV genotype 2a infected in human HuH7 cells assessed as reduction viral RNA level after 72 hrs by RT-PCR method, EC50=0.0054μM. | 27994759 | ||
| HuH7 | Antiviral assay | 24 hrs | Antiviral activity against Hepatitis C virus genotype 1a infected in human HuH7 cells assessed as inhibition of viral replication after 24 hrs presence of 40% NHS, IC50=0.007μM. | 24900473 | ||
| HuH7 | Antiviral assay | 72 hrs | Antiviral activity against HCV genotype 3a infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by RT-PCR method, EC50=0.0072μM. | 26819676 | ||
| HuH7 | Antiviral assay | 72 hrs | Antiviral activity against HCV genotype 3a infected in human HuH7 cells assessed as reduction viral RNA level after 72 hrs by RT-PCR method, EC50=0.0072μM. | 27994759 | ||
| HuH7 | Antiviral assay | 24 hrs | Antiviral activity against Hepatitis C virus (isolate Con1) genotype 1b infected in human HuH7 cells assessed as inhibition of viral replication after 24 hrs in presence of 50% NHS, IC50=0.0074μM. | 24900473 | ||
| HuH7 | Antiviral assay | 72 hrs | Antiviral activity against Hepatitis C virus genotype 3a infected in HuH7 cells assessed as reduction in replicon RNA level after 72 hrs by TaqMan-based RT-PCR analysis in presence of 10% FBS, EC50=0.013μM. | 24900818 | ||
| HBI10A | Antiviral assay | Antiviral activity against Hepatitis C virus subtype 1b infected in HBI10A cells harboring HCV subgenomic bicistronic replicon assessed as reduction in viral replication, EC50=0.002μM. | ChEMBL | |||
| Clicca per visualizzare più dati sperimentali sulle linee cellulari | ||||||
| Peso molecolare | 766.9 | Formula | C38H50N6O9S |
Conservazione (Dalla data di ricezione) | |
|---|---|---|---|---|---|
| N. CAS | 1350514-68-9 | Scarica SDF | Conservazione delle soluzioni stock |
|
|
| Sinonimi | MK5172 | Smiles | CC(C)(C)C1C(=O)N2CC(CC2C(=O)NC3(CC3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=NC6=C(C=CC(=C6)OC)N=C5CCCCCC7CC7OC(=O)N1 | ||
|
In vitro |
DMSO
: 100 mg/mL
(130.39 mM)
Ethanol : 100 mg/mL Water : Insoluble |
|
In vivo |
|||||
Passo 1: Inserire le informazioni di seguito (Consigliato: Un animale aggiuntivo per tenere conto della perdita durante l'esperimento)
Passo 2: Inserire la formulazione in vivo (Questo è solo il calcolatore, non la formulazione. Contattateci prima se non c'è una formulazione in vivo nella sezione Solubilità.)
Risultati del calcolo:
Concentrazione di lavoro: mg/ml;
Metodo per preparare il liquido master di DMSO: mg farmaco predissolto in μL DMSO ( Concentrazione del liquido master mg/mL, Vi preghiamo di contattarci prima se la concentrazione supera la solubilità del DMSO del lotto del farmaco. )
Metodo per preparare la formulazione in vivo: Prendere μL DMSO liquido master, quindi aggiungereμL PEG300, mescolare e chiarire, quindi aggiungereμL Tween 80, mescolare e chiarire, quindi aggiungere μL ddH2O, mescolare e chiarire.
Metodo per preparare la formulazione in vivo: Prendere μL DMSO liquido master, quindi aggiungere μL Olio di mais, mescolare e chiarire.
Nota: 1. Si prega di assicurarsi che il liquido sia limpido prima di aggiungere il solvente successivo.
2. Assicurarsi di aggiungere il/i solvente/i in ordine. È necessario assicurarsi che la soluzione ottenuta, nell'aggiunta precedente, sia una soluzione limpida prima di procedere all'aggiunta del solvente successivo. Metodi fisici come il vortex, gli ultrasuoni o il bagno d'acqua calda possono essere utilizzati per facilitare la dissoluzione.
| Targets/IC50/Ki |
gt1b
(Cell-free assay) 0.01 nM(Ki)
gt1a
(Cell-free assay) 0.01 nM(Ki)
gt1b R155K
(Cell-free assay) 0.07 nM(Ki)
gt2a
(Cell-free assay) 0.08 nM(Ki)
gt1b D168V
(Cell-free assay) 0.14 nM(Ki)
gt2b
(Cell-free assay) 0.15 nM(Ki)
gt1b D168Y
(Cell-free assay) 0.3 nM(Ki)
gt3a
(Cell-free assay) 0.9 nM(Ki)
|
|---|---|
| In vitro |
MK-5172 is a novel P2-P4 quinoxaline macrocyclic NS3/4a protease inhibitor currently in clinical development. The compound demonstrates subnanomolar activity against a broad enzyme panel encompassing major hepatitis C virus (HCV) genotypes as well as variants resistant to earlier protease inhibitors.
|
| In vivo |
In both rat and dog, MK-5172 demonstrates good plasma and liver exposures, with 24-h liver levels suggestive of once-daily dosing. When administered to HCV-infected chimpanzees harboring chronic gt1a or gt1b infections, MK-5172 suppresses viral load between 4 to 5 logs at a dose of 1 mg/kg of body weight twice daily (b.i.d.) for 7 days. MK-5172 demonstrates low to moderate clearance and a modest half-life in both rat and dog. Upon oral administration, MK-5172 demonstrates modest bioavailability of 12 to 13%, with moderate plasma exposure in both species. Significant liver concentrations are achieved in both rat and dog. The 24-h trough liver concentrations are 0.2 μM in rat and 1.4 μM in dog (1 mg per kg), yielding exposure multiples of 27- to 200-fold over the serum-adjusted replicon EC50. MK-5172 proves highly efficacious in vivo at moderate doses against chronic-HCV-infected chimpanzees, including greater viral load suppression than vaniprevir when dosed alternatively to the same animal at an otherwise identical dose and frequency.
|
Riferimenti |
(dati da https://clinicaltrials.gov, aggiornato il 2025-07-15)
| Numero NCT | Reclutamento | Condizioni | Sponsor/Collaboratori | Data di inizio | Fasi |
|---|---|---|---|---|---|
| NCT02940496 | COMPLETED | BCLC Stage B Hepatocellular Carcinoma; BCLC Stage C Hepatocellular Carcinoma; Hepatitis C Infection; Refractory Liver Carcinoma; Stage III Hepatocellular Carcinoma AJCC v7; Stage IIIA Hepatocellular Carcinoma AJCC v7; Stage IIIB Hepatocellular Carcinoma AJCC v7; Stage IIIC Hepatocellular Carcinoma AJCC v7; Stage IV Hepatocellular Carcinoma AJCC v7; Stage IVA Hepatocellular Carcinoma AJCC v7; Stage IVB Hepatocellular Carcinoma AJCC v7 |
M.D. Anderson Cancer Center |
2016-12-09 | PHASE2 |
| NCT03823911 | COMPLETED | Cardiovascular Diseases; Hepatitis C; Hiv |
University of Maryland, Baltimore |
2018-11-18 | PHASE4 |
| NCT02902120 | COMPLETED | Hepatitis C; Renal Insufficiency, Chronic; Disorder of Transplanted Kidney |
University of Maryland, Baltimore |
2017-05-01 | PHASE4 |
| NCT04546802 | WITHDRAWN | Hepatocellular Carcinoma; Hepatoma; Liver Cell Carcinoma; Hepatitis C |
Bayside Health |
2019-09 | PHASE3 |
| NCT03037151 | UNKNOWN | Compensated Cirrhosis |
The HIV Netherlands Australia Thailand Research Collaboration |
2018-08-01 | PHASE4 |
| NCT03026023 | WITHDRAWN | Cardiac Transplant Disorder; Hepatitis C |
Raymond T. Chung, MD |
2018-08-01 | PHASE4 |